window.dotcom = window.dotcom || { cmd: [] }; window.dotcom.ads = window.dotcom.ads || { resolves: {enabled: [], getAdTag: []}, enabled: () => new Promise(r => window.dotcom.ads.resolves.enabled.push(r)), getAdTag: () => new Promise(r => window.dotcom.ads.resolves.getAdTag.push(r)) }; setTimeout(() => { if(window.dotcom.ads.resolves){ window.dotcom.ads.resolves.enabled.forEach(r => r(false)); window.dotcom.ads.resolves.getAdTag.forEach(r => r("")); window.dotcom.ads.enabled = () => new Promise(r => r(false)); window.dotcom.ads.getAdTag = () => new Promise(r => r("")); console.error("NGAS load timeout"); } }, 5000)

Questions over cost of muscular dystrophy drug in Belfast Trust

Catherine Morrison
BBC News NI
Getty A woman (neck below) in a yellow jumper holding a bottle of medicine with an orange wrapper.Getty
The drug, Givinostat, has been approved as safe for use

Questions are being asked over why Belfast Trust is quoting ten times the amount of money to treat young muscular dystrophy sufferers with a new drug as a trust in England.

The issue was raised in the House of Commons by Chris McDonald, MP for Stockton North, who is concerned patients across the UK are facing a "postcode lottery".

The drug, Givinostat, has been approved as safe for use, and the National Institute for Health and Care Excellence (NICE) is due to make a decision on whether to recommend it for use on the NHS later this year.

Despite drug manufacturers offering it for free, Belfast Health Trust, NI's specialist centre for the condition, has so far declined to begin the treatment.

The Belfast Trust has cited the need for "additional staffing resources" as the reason for not offering the drug.

Some trusts in England, Scotland and Wales have already started offering treatment under an early access programme (EAP).

Under a Freedom of Information request, Belfast Trust revealed it had estimated it would cost £309,000 annually to treat 13 patients with the new drug. That's more than £23,000 per patient.

In a separate FOI request, the Oxford University Hospitals said they estimated the cost at £66,000 for 35 to 40 patients: just under £2,000 a head.

'It's like a bottle of Calpol'

Family handout Alfie standing in a football stadium. He has blonde hair and is giving a thumb's up. He's wearing a white and black scarf and football top.Family handout
Alfie was diagnosed with Duchenne muscular dystrophy in 2016

12 year old Alfie Pentony from Newry has Duchenne Muscular Dystrophy.

It is a life-limiting muscle wasting disease which affects boys.

He will eventually need a wheelchair and there is currently no cure but this new drug Givinostat has been shown to keep patients on their feet for longer.

His mother Colleen Pentony said she cannot understand how the Belfast Trust came to their cost estimate.

"It's ridiculous. To me, all they need is a nurse and a consultant.

"They take the medicine at home, I would ister it to Alfie in the morning and night at home.

"It's a stable medicine, you don't even have to keep it refrigerated. It's like a bottle of Calpol."

Family handout Alfie (bottom left) with his family. A woman behind him has blonde hair, wearing a beige coat and black and white striped top. A boy beside him is wearing a a light blue shirt, beige chinos and blue trainers. Alfie is wearing a red coat, light blue shirt, black tros and brown shoes. His dad Jamie is wearing black glasses, a blue check blazer and blue shirt. They are all standing in front of a tree.Family handout
Colleen Pentony said she cannot understand how the Belfast Trust came to the cost estimate

Mrs Pentony said the only additional resources needed would be to facilitate the blood tests the boys need, at first every two weeks, then every three months.

She said Belfast Trust had included a physiotherapist, play therapist and psychologist in the costings.

"These job roles should not be included in this costing. We are supposed to have a physiotherapist already, why would these boys need a play therapist, the boys are all over 6":[]}